Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo citizen petition asks FDA to determine that the company’s old formulation was withdrawn for safety reasons and to decline approval of ANDAs of that formulation; Purdue Pharma files third OxyContin citizen petition.